Trial reportEuropean journal of nuclear medicine and molecular imaging2012
18F-Fluorodeoxyglucose positron emission tomography pulmonary imaging in idiopathic pulmonary fibrosis is reproducible: implications for future clinical trials.
Trial report in European journal of nuclear medicine and molecular imaging, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 56 citations in OpenAlex.
- PulmonaryEuropean journal of nuclear medicine and molecular imaging · 2018Trial
- Pulmonary [European journal of nuclear medicine and molecular imaging · 2026Article
- HDAC11-Mediated Deacetylation of Triosephosphate Isomerase 1 Promotes Idiopathic Pulmonary Fibrosis.Research (Washington, D.C.) · 2025Article
- Imaging at the nexus: how state of the art imaging techniques can enhance our understanding of cancer and fibrosis.Journal of translational medicine · 2024Review
- Optimisation of the air fraction correction for lung PET/CT: addressing resolution mismatch.EJNMMI physics · 2023Article
- PET/CT and inflammatory mediators in systemic sclerosis-associated interstitial lung disease.Jornal brasileiro de pneumologia : publicacao oficial da Sociedade Brasileira de Pneumologia e Tisilogia · 2022Article
- Article
- Imaging Biomarkers in Animal Models of Drug-Induced Lung Injury: A Systematic Review.Journal of clinical medicine · 2020Review
- Early Career Members at the ERS Lung Science Conference 2020: metabolic alterations in lung ageing and disease.Breathe (Sheffield, England) · 2020Article
- The quantitative assessment of interstitial lung disease with positron emission tomography scanning in systemic sclerosis patients.Rheumatology (Oxford, England) · 2020Article
- Review
- Apoptotic PET Imaging of Rat Pulmonary Fibrosis with Small-Molecule Radiotracer.Molecular imaging and biology · 2019Article
- Novel Imaging Approaches in Systemic Sclerosis-Associated Interstitial Lung Disease.Current rheumatology reports · 2019Review
- Article
- Small-animal SPECT/CT imaging of cancer xenografts and pulmonary fibrosis using aBiophysics reports · 2018Article
- PretreatmentTechnology in cancer research & treatment · 2018Article
- [Respiratory research · 2017Article
- Type I collagen-targeted PET probe for pulmonary fibrosis detection and staging in preclinical models.Science translational medicine · 2017Article
- Quantification of Lung PET Images: Challenges and Opportunities.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Review
- Matrix Metalloproteinase-Targeted Imaging of Lung Inflammation and Remodeling.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 5 institutions in 1 country.
Funding
Abstract
purposeNoninvasive markers of disease activity in patients with idiopathic pulmonary fibrosis (IPF) are lacking. We performed this study to investigate the reproducibility of pulmonary (18)F-FDG PET/CT in patients with IPF.
methodsThe study group comprised 13 patients (11 men, 2 women; mean age 71.1 ± 9.9 years) with IPF recruited for two thoracic (18)F-FDG PET/CT studies performed within 2 weeks of each other. All patients were diagnosed with IPF in consensus at multidisciplinary meetings as a result of typical clinical, high-resolution CT and pulmonary function test features. Three methods for evaluating pulmonary (18)F-FDG uptake were used. The maximal (18)F-FDG pulmonary uptake (SUVmax) in the lungs was determined using manual region-of-interest placement. An (18)F-FDG uptake intensity histogram was automatically constructed from segmented lungs to evaluate the distribution of SUVs. Finally, mean SUV was determined for volumes-of-interest in pulmonary regions with interstitial lung changes identified on CT scans. Processing included correction for tissue fraction effects. Bland-Altman analysis was performed and interclass correlation coefficients (ICC) were determined to assess the reproducibility between the first and second PET scans, as well as the level of intraobserver and interobserver agreement.
resultsThe mean time between the two scans was 6.3 ± 4.3 days. The interscan ICCs for pulmonary SUVmax analysis and mean SUV corrected for tissue fraction effects were 0.90 and 0.91, respectively. Intensity histograms were different in only 1 of the 13 paired studies. Intraobserver agreement was also excellent (0.80 and 0.85, respectively). Some bias was observed between observers, suggesting that serial studies would benefit from analysis by the same observer.
conclusionThis study demonstrated that there is excellent short-term reproducibility in pulmonary (18)F-FDG uptake in patients with IPF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.